Abstract
treatment utilizes fiducial markers implanted into the outer table of the skull. Alternatively to the implants, anatomical landmarks on x-rays compared to DRRs can be used for setup. Approximately 200 patients are treated annually with this PSRS system, diagnoses covering malignant (e.g. brain metastases) and benign (e.g. pituitary adenomas, schwannomas, arteriovenous malformations). Efficient procedures have been developed to ensure optimal workflow between the various involved professional groups (immobilization staff, radiation therapy technicians, physicians, neurosurgeons, physicists) to achieve safe and accurate dose delivery. Conclusions: Our institution has developed a unique, efficient, and highly accurate system for delivering PSRS which may serve as a model for other centers. Author Disclosure: J. Daartz: A. Employee; MGH. H.A. Shih: A. Employee; employee: Dartmouth-Hitchcock Medical Center. F. Honoraria; Honoraria: IJROBP. H. Speakers Bureau; Merck. K. Advisory Board; Novartis. P. Royalty; UpToDate. P.H. Chapman: A. Employee; MGH. J.S. Loeffler: A. Employee; MGH. M.R. Bussiere: A. Employee; MGH.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
